Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
181-200 of 397 trials

Rheumatoid Arthritis: Abatacept and Daratumumab Treatment

We are studying a combination of two medications to see if it is safe and effective for people with rheumatoid arthritis who have specific antibodies. This research aims to explore new ways to manage autoimmunity in these patients.

Rheumatoid Arthritis6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Prostate Cancer: PF-06821497 with Enzalutamide

We are studying a new treatment combining PF-06821497 with enzalutamide for men with advanced prostate cancer previously treated with abiraterone. The goal is to see if this combination can improve survival and reduce tumor activity compared to standard therapies.

Castration-resistant Prostate Cancer6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Semaglutide for Mood Improvement in Depression

We are studying if the medication semaglutide can help improve mood in people with major depressive disorder who are also overweight or obese. The trial will measure changes in depressive symptoms and overall well-being.

Unipolar DepressionObesity and Overweight6-12 monthsConfirmation phase (III)Monitoring phase (IV)Investigational MedicinesCost ReimbursementPsychiatry

Lung Fibrosis: ENV-101 Treatment Study

We are testing a new medication, ENV-101, for people with lung fibrosis to see if it improves lung function and overall health. The study will also look at the safety of this treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Type 2 Diabetes: Dapansutrile Study

We are testing a new oral medication for people with type 2 diabetes to see if it helps lower blood sugar levels better than a placebo. The study also looks at its safety and effects on insulin function.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDiabetologyEndocrinology

Tozorakimab: Syringe vs. Autoinjector Study

We are comparing how well Tozorakimab works when given through a prefilled syringe versus an autoinjector. This study aims to understand the differences in how the body absorbs the medication.

InflammationRespiratory Issues6-12 monthsSafety phase (I)Pulmonology

Dapagliflozin for Decompensated Liver Cirrhosis

We are studying whether dapagliflozin is safe and effective for patients with decompensated liver cirrhosis compared to standard treatments. The trial also looks at how it may affect quality of life and various health markers.

Decompensated Liver Cirrhosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Alpha-1 Antitrypsin Deficiency: WVE-006 Treatment

We are testing a new treatment called WVE-006 for people with Pi*ZZ Alpha-1 Antitrypsin Deficiency. The study aims to evaluate its safety and how the body responds to it.

Alpha-1 Antitrypsin Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyGastroenterologyHepatologyInternal MedicinePulmonology

Short Bowel Syndrome: Crofelemer Study

We are testing crofelemer to see if it helps adults with Short Bowel Syndrome and Intestinal Failure manage their symptoms better. The study will assess its safety and effectiveness compared to a placebo.

Short Bowel Syndrome and Intestinal Failure6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Progressive Vitiligo: Anifrolumab and Phototherapy Study

We are investigating whether combining anifrolumab with phototherapy helps adults with progressive vitiligo regain skin color better than phototherapy alone. The study will also assess the safety and tolerability of this new treatment approach.

Vitiligo6-12 monthsEfficacy phase (II)Standard MedicinesAllergologyDermatology

Glucothera Plus for Children on Peritoneal Dialysis

We are studying the safety of Glucothera Plus in children receiving peritoneal dialysis. We also want to see if it helps restore L-carnitine levels in these patients.

End-stage Kidney Disease6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

Irritable Bowel Syndrome: Symbioflor®2 Treatment

We are studying an oral treatment with living bacteria for people with diarrhea-predominant irritable bowel syndrome (IBS-D). The goal is to see if it helps reduce symptoms compared to a placebo.

Irritable Bowel Syndrome6-12 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementGastroenterology

Generalized Myasthenia Gravis: Telitacicept Study

We are testing a new treatment called telitacicept for people with generalized myasthenia gravis. The study aims to see if it works better than a placebo and to check its safety.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurologyRheumatology

Pancreatic Cancer: Digitoxin and Chemotherapy Study

We are exploring whether adding digitoxin to chemotherapy can help improve survival for patients with inoperable pancreatic cancer. The trial also looks at treatment safety and quality of life.

Pancreatic Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Kidney Health: SGLT2 Inhibitor for Prediabetes

We are studying whether adding a new medication to lifestyle changes can help improve kidney function in people with prediabetes. This trial will help us understand its potential benefits for kidney health.

Early Stage Chronic Kidney Disease6-12 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesEndocrinologyNephrology

LPH-5: First-in-Man Safety Study

We are investigating a new drug called LPH-5 in healthy volunteers to see how safe it is and how it works in the body. This study will help us understand its effects compared to a placebo.

Depression6-12 monthsSafety phase (I)Psychiatry

Hemolytic Uremic Syndrome: INM004 Treatment for Kids

We are studying a new treatment for children with Hemolytic Uremic Syndrome caused by E. coli to see if it helps improve kidney function and reduce complications. The trial will also evaluate the safety of this treatment.

Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesNephrologyPediatrics

Plaque Psoriasis: Zasocitinib vs. Deucravacitinib

We are studying whether a new oral medication, zasocitinib, is more effective than deucravacitinib for treating moderate-to-severe plaque psoriasis. The trial will also assess the safety and tolerability of both treatments.

Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

GRT7040: First-in-Human Safety Study

We are testing a new medication called GRT7040 in healthy volunteers to see how safe it is and how the body processes it. This study aims to gather important information before it can be used in patients.

Pain6-12 monthsSafety phase (I)AllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyHepatologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryPulmonologyRheumatologyUrology

Triple-Negative Breast Cancer: NECVAX-NEO1 Treatment

We are studying the safety and effects of NECVAX-NEO1 added to standard PD-1 inhibitor therapy for patients with triple-negative breast cancer. This trial aims to see if the new treatment can enhance cancer response and improve outcomes.

Triple Negative Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology